Author: Ravi Shankar

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — Q-Gold Resources Ltd. (“QGold” or the “Company”) is pleased to announce the appointment of Rodrigo Costa, M.Sc., as Vice President – Technical Services and Engineering.

Mr. Costa is a mining engineer with more than three decades of international experience in project development, engineering, construction, commissioning and operational management. He has held senior leadership roles with a number of leading mining companies, where he built a strong track record leading engineering studies, mine operations and development projects focused predominantly on gold and precious metals. Mr. Costa has experience developing complex projects in environmentally sensitive areas, and has successfully managed multi-discipline engineering studies and metallurgical test work programs across a range of gold operations internationally.

“Rodrigo brings deep technical expertise in gold processing and metallurgy, along with a proven track record of delivering engineering and feasibility studies for mining projects around the world,” said Peter Tagliamonte, Chief Executive Officer of QGold. “His international experience managing complex, multi-discipline projects — including in environmentally sensitive settings, and his strong hands-on operational expertise — will be a significant asset as we advance Quartz Mountain and Mine Centre. We are very pleased to welcome him to the QGold team.”

Mr. Costa holds an Engineering degree and a Master of Science in Engineering from Queen’s University in Canada, internationally recognized as one of the premier mining and metallurgical universities.

“I am excited to join QGold at an important stage in the Company’s development,” said Mr. Costa. “I look forward to applying my experience in engineering, project execution and operations to support the responsible advancement of Quartz Mountain and Mine Centre.”

About Q-Gold Resources Ltd.

Q-Gold Resources Ltd. is a Canadian gold development and exploration company focused on advancing high-quality gold assets in North America. The Company’s primary assets are the Quartz Mountain Gold Project in Oregon, USA, and the Mine Centre Gold Project in Ontario, Canada.

QGold remains focused on disciplined project advancement, responsible resource development and long-term shareholder value creation through the development and exploration of high-quality North American gold assets.

For further information, please contact:
Peter Tagliamonte
Chairman & Chief Executive Officer
Cell: +1 (416) 564-2880
Q-Gold Resources Ltd.
info@qgoldresources.com | www.qgoldresources.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) — AGF Investments Inc. (AGF Investments) (TSX:AGF.B) today announced the September 2026 cash distributions for AGF Enhanced U.S. Equity Income Fund*, AGF Enhanced U.S. Income Plus Fund*, AGF Total Return Bond Fund* and AGF Systematic Global Infrastructure ETF, which pay monthly distributions. Unitholders of record on September 30, 2026 will receive cash distributions payable on October 6, 2026. 

Details regarding the final “per unit” distribution amounts are as follows:

ETF	Ticker	Exchange	Cash Distribution Per Unit ($)
AGF Enhanced U.S. Equity Income Fund*	AENU	Cboe Canada Inc.	$0.198597
AGF Enhanced U.S. Income Plus Fund*	AENP	Toronto Stock Exchange	$0.207605
AGF Total Return Bond Fund*	ATRB	Cboe Canada Inc.	$0.106000
AGF Systematic Global Infrastructure ETF	QIF	Cboe Canada Inc.	$0.160740

^{*AGF Enhanced U.S. Equity Income Fund, AGF Enhanced U.S. Income Plus Fund and AGF Total Return Bond Fund are mutual funds with an ETF series option.}

Further information about the AGF ETFs can be found at AGF.com.

This information is not intended to provide legal, accounting, tax, investment, financial, or other advice, and should not be relied upon for providing such advice. Commissions, trailing commissions, management fees and expenses all may be associated with investment fund investments. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated. AGF ETFs are ETFs offered by AGF Investments Inc. ETFs are listed and traded on organized Canadian exchanges and may only be bought and sold through licensed dealers.

The distribution is not guaranteed, may be adjusted from time to time at the discretion of the fund manager and may vary from payment to payment. The payment of distributions should not be confused with a fund’s performance, rate of return or yield. If distributions paid by the fund are greater than the performance of the fund, the original investment will shrink. Distributions paid as a result of capital gains realized by a fund, and income and dividends earned by a fund, are taxable to the investor in the year they are paid. The adjusted cost base will be reduced by the amount of any returns of capital. If the adjusted cost base falls below zero, the investor will have to pay capital gains tax on the amount below zero.

About AGF Management Limited

Founded in 1957, AGF Management Limited (AGF) is an independent and globally diverse asset management firm. Our companies deliver excellence in investing in the public and private markets through three business lines: AGF Investments, AGF Capital Partners and AGF Private Wealth.

AGF brings a disciplined approach, focused on incorporating sound, responsible and sustainable corporate practices. The firm’s collective investment expertise, driven by its fundamental, quantitative and alternative investing capabilities, extends globally to a wide range of clients, from financial advisors and their clients to high-net worth and institutional investors including pension plans, corporate plans, sovereign wealth funds, endowments and foundations.

Headquartered in Toronto, Canada, AGF has investment operations and client servicing teams on the ground in North America and Europe. With over $74 billion in total assets under management and fee-earning assets, AGF serves more than 820,000 investors. AGF trades on the Toronto Stock Exchange under the symbol AGF.B.

About AGF Investments

AGF Investments is a group of wholly owned subsidiaries of AGF Management Limited, a Canadian reporting issuer. The subsidiaries included in AGF Investments are AGF Investments Inc. (AGFI), AGF Investments LLC (AGFUS) and AGF International Advisors Company Limited (AGFIA). The term AGF Investments may refer to one or more of these subsidiaries or to all of them jointly. This term is used for convenience and does not precisely describe any of the separate companies, each of which manages its own affairs.

AGF Investments entities only provide investment advisory services or offers investment funds in the jurisdiction where such firm and/or product is registered or authorized to provide such services.

AGF Investments Inc. is a wholly-owned subsidiary of AGF Management Limited and conducts the management and advisory of mutual funds in Canada.

Media Contact

Amanda Marchment
Director, Corporate Communications
416-865-4160
amanda.marchment@agf.com

Former CFO, Board Member and Investment Leader to Advise Power, Energy and Infrastructure Clients on Growth, Capital Allocation, Performance Improvement and Restructurings

WASHINGTON, Sept. 22, 2026 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of Eileen Fargis as a Senior Managing Director in the global Power, Renewables & Energy Transition practice.

Ms. Fargis, who is based in New York, joins FTI Consulting with three decades of experience across conventional and renewable power, energy transition and infrastructure businesses globally.

In her role at FTI Consulting, Ms. Fargis will advise clients across power, energy and infrastructure sectors as they respond to accelerating electricity demand, data center and AI growth, capital constraints, national security issues, macro and supply-chain challenges and an evolving regulatory environment. Her work will focus on strategic, financial and operational matters, including capital deployment, transaction advisory, performance optimization and financial turnarounds, and portfolio company and board-level advisory.

“Eileen has worked on all sides of the table, as an investor, lender, senior executive, board member and advisor,” said Chris LeWand, Global Leader of the Power, Renewables & Energy Transition practice at FTI Consulting. “She has done it extensively internationally and domestically and brings practical, real-world expertise to helping clients make critical strategic, financial and operational decisions.”

Ms. Fargis has held senior investment roles at GE Energy Financial Services, IFC Asset Management Company and InterEnergy Holdings, including co-heading a multi-sector private equity fund, leading investments for a multinational power company and supporting major infrastructure platform expansion and acquisition initiatives. She also has served in senior operating and leadership roles within energy companies, most recently as Chief Financial Officer and Chief Growth Officer of a U.S. power developer, where she helped guide the business through a period of rapid growth and strategic transitions. She has also advised energy and infrastructure companies, investors and boards through Overlook Energy Advisors.

Ms. Fargis has served as a board director and committee member for energy and infrastructure-related companies in the United States, Latin America and other international markets, bringing governance experience across audit, compensation and leadership transition matters, as well as a broad perspective on complex capital allocation, operational and portfolio decisions.

Commenting on her appointment, Ms. Fargis said, “The power and energy sectors are going through an unusually dynamic period, driven by growing demand for electricity, regulatory changes, capital constraints and shifting investor expectations. Companies and investors are making increasingly complex decisions about capital deployment, growth strategies and operating models. I look forward to joining the team at FTI Consulting and helping clients navigate these challenges, protect and create value, and make informed strategic and capital allocation decisions.”

About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 32 countries and territories as of June 30, 2026. In certain jurisdictions, FTI Consulting’s services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.8 billion in revenues during fiscal year 2025. More information can be found at www.fticonsulting.com.

FTI Consulting, Inc.  
555 12^th Street NW  
Washington, DC 20004  
+1.202.312.9100 

Investor Contact:  
Mollie Hawkes 
+1.617.747.1791 
mollie.hawkes@fticonsulting.com 

Media Contact:  
Sam Ford 
+1.617.480.7402
samantha.ford@fticonsulting.com

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced a partnership to integrate the iLet Bionic Pancreas and mint automated insulin delivery (AID) systems with Senseonics’ Eversense 365 continuous glucose monitoring (CGM) system.

Commercial launch of the integrated iLet and Eversense 365 system is expected in the fourth quarter of 2026, at which time Beta Bionics expects iLet to support the most CGM manufacturer options of any AID system, maximizing choice for its users.

The companies have also committed to the integration of mint and Eversense 365 in the future. This partnership underscores Beta Bionics’ and Senseonics’ shared commitment to bringing cutting-edge diabetes solutions to the market, while maximizing choice for people living with diabetes.

“This collaboration with Senseonics will expand our reach to a larger group of people with diabetes and empower them with maximum choice in the devices they rely on to manage their diabetes,” said Sean Saint, President & CEO of Beta Bionics. “We believe the combination of our fully adaptive AID platform with year-long glucose sensing offers a compelling and differentiated choice for people with diabetes in finding the system that is right for them.”

About Beta Bionics

Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. Beta Bionics’ proprietary insulin dosing algorithm is the first FDA-cleared algorithm that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding: expectations of Beta Bionics, Inc. (the “Company”) regarding the integration of iLet and mint with Eversense 365, the timing or certainty of commercial launch of iLet and mint with Eversense 365 integration; and the implications and potential benefits of iLet and mint integration with Eversense 365. Words such as “believe,” “anticipate,” “plan,” “expect,” “intend,” “will,” “may,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements, though not all forward-looking statements necessarily contain these identifying words. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties, including business, regulatory, economic and competitive risks and uncertainties about the Company, risks inherent in developing product candidates, the Company’s ability to obtain adequate financing to fund its product development and other expenses, the Company’s ability to manufacture and scale production of its products and manage its supply chain, the Company’s ability to obtain adequate reimbursement and payer coverage for its products, trends in the industry, the Company’s relationships with its existing and future collaboration partners, the legal and regulatory framework for the industry, future expenditures and the potential impacts of global macroeconomic conditions. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results and the variations may be material. Other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Source: Beta Bionics, Inc.

Canadian-developed autonomy platform successfully navigates without GPS, external sensors, or high-performance computing

VAUGHAN, Ontario, Sept. 22, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQX: TAKOF) (FSE: ABB.F) (“Volatus” or the “Company”), a Canadian-headquartered global aerospace and defence company, today announced the successful completion of initial flight testing of its proprietary V-Cortex™ AI Flight Controller and Autonomy Operating System.

The testing successfully demonstrated GNSS-denied navigation without reliance on external sensors, using onboard default sensors to maintain flight. This breakthrough represents a major advancement in autonomous operations in environments where GPS signals are unavailable, degraded, or intentionally disrupted, including contested environments, dense urban areas, and remote regions such as Canada’s Arctic.

“At CANSEC, we introduced V-Cortex as Canada’s sovereign autonomy platform. These initial flights move the platform from development to demonstrated performance,” said Glen Lynch, Chief Executive Officer of Volatus. “Successfully navigating without GPS or external sensors is a major technical milestone that validates our approach to resilient autonomy. It brings us one step closer to delivering a Canadian-developed solution for defence, public safety, and critical infrastructure operators.”

V-Cortex is designed as a common autonomy layer, platform agnostic and multi-domain, that can be integrated across multiple uncrewed aircraft platforms. Its open, modular architecture allows Volatus to advance new aircraft and mission capabilities without developing a separate autonomy system for each platform, supporting faster integration, greater scalability and sovereign control of critical flight technologies.

Designed and developed entirely in Canada, V-Cortex combines advanced flight control, AI-enabled autonomy, and an open, modular architecture to support a broad range of uncrewed aircraft systems. Development of the V-Cortex autonomy stack continues to be supported through advisory services and funding from the National Research Council of Canada’s Industrial Research Assistance Program (NRC IRAP) through its Defence Industry Assist initiative.

Additional flight testing and capability demonstrations are planned throughout 2026 as Volatus advances the V-Cortex platform toward operational deployment across its growing family of autonomous systems.

About Volatus Aerospace Inc. 

Volatus Aerospace is a Canadian-controlled global aerospace and defence company delivering integrated uncrewed systems, aerial intelligence, and mission-critical operational services. The Company provides unmanned aerial systems, aerial intelligence services, autonomy software, and advanced training solutions supporting civil infrastructure, public safety, and defence markets. 

Forward-Looking Information 

This news release contains statements that constitute “forward-looking information” and “forward-looking statements” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs, and current expectations of the Company with respect to future business activities, events, developments and operating performance. Often, but not always, forward-looking information and forward-looking statements can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “seeks”, “strategy” or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass. Forward-looking information includes information regarding: (i) the business plans, business outlook and expectations of the Company; and (ii) expectations for other economic, business, and/or competitive factors. 

Forward-looking information is based on currently available competitive, financial, and economic data and operating plans, strategies, or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to the Company, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement. 

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Forward-looking information and forward-looking statements reflect the Company’s current beliefs and is based on information currently available to it and on assumptions it believes to be not unreasonable in light of all of the circumstances. In some instances, material factors or assumptions are discussed in this news release in connection with statements containing forward-looking information. Such material factors and assumptions include but are not limited to: the commercialization of drone flights beyond visual line of sight and potential benefits to the Company; and meeting the continued listing requirements of the TSX. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. The forward-looking information contained herein is made as of the date of this news release and, other than as required by law, the Company disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. 

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release. 

For additional information, please contact: 

Volatus Aerospace Inc. 
Rob Walker, Chief Commercial Officer
+1-833-865-2887
investorrelations@volatusaerospace.com
https://volatusaerospace.com

HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) — CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide^® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. BCBSM serves approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shield of Michigan and Blue Care Network, one of the nation’s largest nonprofit Blue Cross Blue Shield organizations. Combined with previously announced agreements, CNSide has now established contracted reimbursement coverage representing approximately 158 million commercial and Medicare Advantage covered lives, reflecting continued execution of the Company’s national reimbursement strategy.

“This agreement with Blue Cross Blue Shield of Michigan represents another important milestone in our commercialization strategy to expand patient access to CNSide,” said Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome. “With BCBSM, CNSide now has contracted commercial and Medicare Advantage coverage representing approximately 158 million covered lives, further strengthening our national reimbursement platform and expanding patient access across the U.S.”

The BCBSM agreement represents the latest milestone in CNSide’s strategy to establish broad reimbursement coverage across the U.S. Commercial payer coverage is a key driver of physician adoption, patient access, and commercial utilization of laboratory-developed diagnostic tests such as CNSide^®.

The CNSide^® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide^® over standard of care has been shown in 12 peer-reviewed publications and prospective multicenter evidence from the FORESEE clinical study, and has been supported by real-world clinical experience.

Since 2020, more than 11,000 CNSide^® tests have been performed at over 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.

This test is available exclusively through CNSide Diagnostics, LLC, as a testing service provided to health care professionals in the U.S.

About CNSide Diagnostics, LLC 
CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide^®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide^® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.

About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide^® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value, visit https://www.cerenome.com. 

About Blue Cross Blue Shield of Michigan
Blue Cross Blue Shield of Michigan, a nonprofit mutual insurance company, is an independent licensee of the Blue Cross and Blue Shield Association. Blue Cross provides health benefits to more than 4.7 million members residing in Michigan in addition to employees of Michigan-headquartered companies residing outside the state. The company has been committed to delivering affordable health care products through a broad variety of plans for businesses, individuals and seniors for more than 80 years. Beyond health care coverage, Blue Cross supports impactful community initiatives and provides leadership in improving health care. For more information, visit bcbsm.com and MiBlueDaily.com.

Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.

Investor Contact
CORE IR
IR@cerenome.com

New facility expected to expand capacity by approximately CAD $250 million annually, with potential for approximately CAD $400 million upon full site build-out

GUELPH, Ontario, Sept. 22, 2026 (GLOBE NEWSWIRE) — Hammond Power Solutions Inc. (“HPS” or “Company”; TSX: HPS.A), a leading provider of magnetic and power electronic solutions, announced that it has signed a long-term lease for a new manufacturing facility in Fort Worth, Texas. The facility will expand HPS’s ability to serve U.S.-based customers requiring large standard and custom-engineered transformers. The Fort Worth facility is strategically located to improve proximity to key customers, shorten delivery distances for certain products and enhance HPS’s ability to serve core end markets.

“HPS has built a strong manufacturing platform through its operations in Canada and Mexico, and those facilities will continue to be an important part of how we serve the North American market. This new investment in a U.S. facility is about being closer to our customers and better positioned to support the long-term demand we are seeing for our products,” said Adrian Thomas, Chief Executive Officer of HPS. “Demand for transformers continues to increase, particularly from large projects tied to data centres, electrification and power infrastructure. The Fort Worth facility gives us additional capacity in the U.S. to improve responsiveness, support shorter delivery distances for certain customers, and help us continue to provide the reliability and service our customers expect from HPS.”

Production activities at the facility are expected to commence in stages beginning in Q4 2027. Once the initial production phase commences, the facility is expected to add approximately CAD $250M of manufacturing capacity, based on anticipated demand and normal course operating assumptions. HPS expects to invest approximately CAD $50 million to equip and commission the initial production phase, which it anticipates funding through its existing cash and credit facilities.

The facility was selected, in part, because of its potential to support additional capacity over time. Subject to market demand, future capital investment and other relevant factors, the site could support total annual manufacturing capacity of approximately CAD $400 million.

“Over the past several years, we have made significant investments to enhance efficiency, throughput and capacity across our manufacturing operations in Canada and Mexico,” said John Bailey, Chief Operations Officer of HPS. “The Fort Worth facility provides an opportunity to apply the operational disciplines, manufacturing processes and lessons learned from those investments in a purpose-built environment designed to support future growth. The facility will enhance our manufacturing flexibility, increase our ability to scale efficiently and reinforce the quality, consistency and reliability that define HPS.”

Caution Regarding Forward-Looking Information

This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements that relate to, among other things, HPS’s strategies, intentions, plans, beliefs, expectations and estimates, in connection with general economic and business outlook, prospects and trends of the industry, expected demand for products and services, product development and the Company’s competitive position, including statements regarding the expected outcome of the proposed capacity expansion and related costs of such capacity and its effects on HPS’ operational capabilities, market reach and growth profile, and the drivers thereof, as well as the expected sources of funding for such activities. Forward-looking statements can generally be identified, but not limited to, the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective” and “continue” and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. There can be no assurance that the expected initial manufacturing capacity, any future increase in capacity, related capital investments, customer demand, pricing assumptions or other operating assumptions will be achieved, proceed as currently contemplated or materialize at all. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from expectations include but are not limited to: general business and economic conditions (including but not limited to risks related to foreign currency fluctuations, changing interest rates, and the availability of external capital); risks associated with the Company’s business environment (such as risks associated with the financial condition of the data centre market, electrification and power infrastructure, oil and gas, mining and infrastructure project business); geopolitical risks; climate related risks; changes in laws and regulations; operational risks (such as risks related to existing and developing new products and services; doing business with partners and suppliers; product sales and performance; legal and regulatory proceedings; dependence on certain customers and suppliers; costs associated with raw materials, products and services; human resources; and the ability to execute strategic plans); risk associated with non-completion of the capacity expansion, risks associated with the development, equipping, commissioning and ramp-up of new manufacturing facilities, including construction or fit-out delays, cost overruns, permitting or regulatory delays, delays in the delivery or installation of equipment, availability of qualified labour, supply chain disruptions, customer demand not materializing as expected, price compression, and the facility not achieving expected production capacity, timing, efficiencies or financial returns.

The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

This forward-looking information represents our views as of the date of this press release and such information should not be relied upon as representing our views as of any date subsequent to the date of this press release. We have attempted to identify important factors that could cause actual results, performance or achievements to vary from those current expectations or estimated, expressed or implied by the forward-looking information. However, there may be other factors that cause results, performance or achievements not to be as expected or estimated and that could cause actual results, performance or achievements to differ materially from current expectations.

There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those expected or estimated in such statements. Accordingly, readers should not place undue reliance on forward-looking information.

About Hammond Power Solutions Inc.

HPS enables electrification through its portfolio of power conversion, power distribution and power quality solutions, including dry-type transformers, power electronics and related products used across critical electrical infrastructure and industrial applications. The Company has manufacturing plants in North America, Europe, and Asia, and sells its products around the globe. HPS shares are listed on the Toronto Stock Exchange and trade under the symbol HPS.A.

For further information, please contact:
David Feick
Investor Relations
519-822-2441
ir@hammondpowersolutions.com

Dr. Vnuk brings substantial business and corporate development leadership experience from Sanofi, Blackstone, and Pfizer

CAMBRIDGE, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Monika Vnuk, MD, as Chief Business Officer. Dr. Vnuk will join Wave’s executive team and lead business development, corporate development, and alliance management.

“We are thrilled to welcome Dr. Vnuk to Wave in a newly created leadership role as we continue to advance our pipeline to the next stages of development. Monika’s breadth of experience, including leading global business development teams and strategic asset financing, will be meaningful as we continue to expand the potential of our differentiated RNA medicines platform and support the next phase of Wave’s growth,” said Paul Bolno, MD, MBA, President and Chief Executive Officer of Wave Life Sciences.

“Wave has built a highly versatile and differentiated RNA medicines platform with multiple therapeutic modalities translating in the clinic. I am energized to join the company at such an exciting moment, as its science and pipeline programs create broad opportunity to advance value-creating transactions with the ultimate aim of expanding Wave’s positive impact on patients. I look forward to partnering with the Wave team to help drive the company’s growth and realize the full potential of its platform and pipeline,” said Monika Vnuk, MD, Chief Business Officer of Wave Life Sciences.

Prior to joining Wave, Dr. Vnuk served as Senior Vice President, Global Head of Partnering and Business Development for Sanofi, where she led global licensing, equity investments, and alliances. Prior to Sanofi, she was Managing Director at Blackstone Life Sciences, a private life sciences investing platform, where she was focused on late-stage product financing transactions. Dr. Vnuk spent more than a decade at Pfizer in senior business development roles, including Vice President, R&D Business Development, where she led the negotiation of the successful partnership with BioNTech directed at the global co-development and distribution of COVID-19 vaccines. Before Pfizer, she worked in investment banking at Bank of America and the life sciences venture capital firm Oxford Bioscience Partners. Dr. Vnuk earned an M.D. from Boston University School of Medicine and a B.A. in Mathematics and Philosophy from Boston University.

In connection with Dr. Vnuk joining Wave, she received a stock option to purchase 375,000 shares of common stock of Wave. The equity grant was approved by Wave’s Compensation Committee and granted to Dr. Vnuk on September 21, 2026, outside of the Wave Life Sciences, Inc. Amended and Restated 2021 Equity Incentive Plan, as an inducement material to Dr. Vnuk’s commencing employment with Wave, in accordance with Nasdaq Stock Market Listing Rule 5635(c)(4). The option has an exercise price of $4.25 per share, the closing price on the grant date, and vests over four years with 25% vesting on September 21, 2027, and the remainder vesting in equal quarterly installments over the following three years.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Dr. Vnuk’s leadership and global experience leading business development teams and strategic asset financing, strategic partnerships, licensing, equity investments and alliances; beliefs that Dr. Vnuk’s experience will benefit the next phase of Wave’s growth; beliefs that Wave’s portfolio of RNA medicines is differentiated, best-in-class and potentially transformative; the broad potential of Wave’s RNA medicines pipeline and oligonucleotide chemistry and any benefits that may be derived from them. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release and actual results may differ materially from those indicated by these forward-looking statements as a result of these risks, uncertainties and important factors, including, without limitation, the risks and uncertainties described in the section entitled “Risk Factors” in Wave’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as amended, and in other filings Wave makes with the SEC from time to time. Wave undertakes no obligation to update the information contained in this press release to reflect subsequently occurring events or circumstances.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
InvestorRelations@wavelifesci.com

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
MediaRelations@wavelifesci.com

BOSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders (CervoMed or the Company), today announced that Company management will participate in a panel discussion and one-on-one meetings at the upcoming 5th Annual ROTH Healthcare Opportunities Conference being held in New York, NY, on Tuesday, September 29, 2026.

Panel Details
Title: “Frontiers in Neuroscience”
Date: Tuesday, September 29, 2026
Time: 10:00 AM – 10:50 AM ET

This panel will not be webcast. A recording of the panel will be available following the conference. To request a meeting or for more details about the Conference, please reach out to your institutional representative at Roth or contact cervomed@argotpartners.com. 

About CervoMed

CervoMed is a clinical-stage company developing treatments for age-related brain disorders. Its lead drug candidate, neflamapimod, is an oral small molecule targeting critical disease processes underlying degenerative disorders of the brain by inhibiting a key enzyme involved in neuroinflammation and neurodegeneration. CervoMed’s recently completed Phase 2b RewinD-LB trial evaluated neflamapimod in patients with DLB, enriched for those without AD co-pathology, and the Company announced alignment with the FDA on a potential registration path for neflamapimod in DLB in November 2025. Initiation of a Phase 3 trial in DLB is subject to the establishment of a partnership and/or additional financing. CervoMed also recently completed enrollment in its ongoing Phase 2a clinical trial evaluating neflamapimod in nfvPPA, a subtype of frontotemporal disorders, from which interim biomarker data is anticipated in the early fourth quarter of 2026, and expects the first patient to be dosed with neflamapimod in the EXPERTS-ALS Phase 2a clinical trial in the fourth quarter of 2026.

Contacts:

Media:
Lisa Guiterman
Biongage Communications
lisa.guiterman@gmail.com
202-330-3431

Investor Relations:
Argot Partners
cervomed@argotpartners.com
212-600-1902 

ROUYN-NORANDA, Québec, Sept. 22, 2026 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX-V – FPC) (“Falco” or the “Corporation”) is proud to announce a three-year partnership with the Collectif Territoire, an organization committed to the rehabilitation of lac Osisko and to mobilizing the community around this emblematic space in Rouyn-Noranda. As part of this partnership, Falco will contribute $30,000 per year for three years, for a total commitment of $90,000. The public announcement of this partnership is part of the activities surrounding “Les Noces d’eau” event.

For Falco, this commitment goes far beyond financial support. The Collectif Territoire’s approach, based on co-creation, territorial innovation, environmental restoration and citizen participation, is directly in line with the vision that Falco wishes to put forward in the development of Falco’s Horne 5 Project. The Corporation intends to build a lasting relationship with the Rouyn-Noranda community, in which citizens can contribute to discussions about the territory and participate in initiatives that benefit their community.

“The lac Osisko Project exemplifies the kind of initiative we want to support in Rouyn-Noranda: a collaborative and place-based approach that brings residents together around sustainable environmental and community projects. Our partnership with the Collectif Territoire is a concrete expression of the relationship that Falco seeks to build with the community,” said Hélène Cartier, Vice-President, Environment, Sustainable Development and Community Relations at Falco.

Update on Falco’s Horne 5 Project
This commitment comes as Falco’s Horne 5 Project continues to move forward. Preparatory work on the project has now been underway for more than ten years. The environmental assessment conducted by the Government of Québec is now at an advanced stage and is expected to be completed in the fall of 2026.

Since the publication of the BAPE report in January 2025, Falco has responded to several sets of questions from the Ministry of the Environment, the Fight against Climate Change, Wildlife and Parks (“MELCCFP”), particularly regarding the potential impacts of the project on community services, including health care, childcare and education services, housing, emergency services and the workforce. These issues have been the subject of in-depth analyses, particularly in the Socioeconomic Assessment (in French only) published last spring.

In addition, the potential impact of project-related vibrations on the safety and continuity of operations at the Rouyn-Noranda Radiation Oncology Centre (the “Centre”) has been thoroughly assessed by independent experts, who confirmed that the mining operations and mitigation measures proposed by Falco can be carried out safely and in a manner compatible with the activities of the Centre (see Falco’s press release dated June 16, 2026).

The completion of the environmental assessment should lead to a government decision regarding the issuance of the authorization decree for the Project (the “Decree”). Obtaining the Decree will mark a decisive step for Falco and will pave the way for the development phase of the Project after obtaining all the required permits and ministerial authorizations. In the months following the Decree, Falco will continue to carry out the required studies and investigations.

The updated feasibility study published on June 17, 2026 also confirms the extent of the anticipated benefits of Falco’s Horne 5 Project for Rouyn-Noranda and Abitibi-Témiscamingue. This project represents an initial planned investment of $1.75 billion, a mine life of at least 15 years, the creation of 500 permanent jobs as well as more than $4.4 billion in taxes and mining duties over the life of the mine.

For Falco, the development of a mining project of this magnitude must be accompanied by a lasting commitment to the community that hosts it. The partnership with the Collectif Territoire is therefore part of a broader vision: to make Falco’s Horne 5 Project not only an economic driver for the region, but also a tangible contributor to the vitality, environment and quality of life of the Rouyn-Noranda community.

To learn more about:

• Collectif Territoire’s lac Osisko Project (in French): https://www.lacosisko.ca/
• The Falco Horne 5 Project (in French): Home | Falco Horne 5
• Falco Resources: Home | Ressources Falco

About Falco

Falco is one of the largest holders of mineral claims in the province of Québec, with an extensive portfolio of properties in the Abitibi-Témiscamingue greenstone belt. Falco holds rights to approximately 60,000 hectares of land in the Noranda Camp and includes 13 former gold and base metal mine sites. Falco’s main asset is the Horne 5 Project located beneath the former Horne mine, which was operated by Noranda from 1927 to 1976 and produced 11.6 million ounces of gold and 2.5 billion pounds of copper. Osisko Gold Group Inc. (formerly Osisko Development Corp.) is Falco’s largest shareholder, with a 16.0% interest in the Corporation.

For further information, please contact:

Luc Lessard
President and Chief Executive Officer and Director
514-261-3336
info@falcores.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.